Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Other Working Capital Changes: 2021-2025

Historic Other Working Capital Changes for ARS Pharmaceuticals (SPRY) over the last 4 years, with Sep 2025 value amounting to -$1.1 million.

  • ARS Pharmaceuticals' Other Working Capital Changes fell 312.10% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 million, marking a year-over-year increase of 742.90%. This contributed to the annual value of $6.2 million for FY2024, which is 297.35% up from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Other Working Capital Changes of -$1.1 million as of Q3 2025, which was up 73.92% from -$4.1 million recorded in Q2 2025.
  • ARS Pharmaceuticals' Other Working Capital Changes' 5-year high stood at $7.3 million during Q4 2024, with a 5-year trough of -$4.1 million in Q2 2025.
  • Over the past 3 years, ARS Pharmaceuticals' median Other Working Capital Changes value was -$697,000 (recorded in 2024), while the average stood at $298,000.
  • In the last 5 years, ARS Pharmaceuticals' Other Working Capital Changes crashed by 6,870.00% in 2024 and then surged by 653.17% in 2025.
  • Quarterly analysis of 5 years shows ARS Pharmaceuticals' Other Working Capital Changes stood at -$1.7 million in 2021, then plummeted by 410.81% to -$189,000 in 2022, then surged by 97.84% to -$10,000 in 2023, then tumbled by 6,870.00% to $7.3 million in 2024, then slumped by 312.10% to -$1.1 million in 2025.
  • Its Other Working Capital Changes was -$1.1 million in Q3 2025, compared to -$4.1 million in Q2 2025 and $4.8 million in Q1 2025.